Linked Life Data

19326440

Source:http://linkedlifedata.com/resource/pubmed/id/19326440

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2009-5-4
pubmed:abstractText
Nicotinic acetylcholine receptors (nAChR) are expressed on bronchial epithelial and non-small cell lung cancer cells and are involved in cell growth regulation. Nicotine (classical nAChR agonist) induced cell proliferation, whereas nAChR antagonists, d- tubocurarine or alpha-cobratoxin (alpha-CbT), induced cell death. In the current study, we further explored the antitumor potential mechanisms and activities of alpha-CbT. NOD/SCID mice were grafted intraperitoneally or orthotopically and treated with alpha-CbT. alpha-CbT treatment [0.04 ng/kg or 0.12 ng/kg] induced a strong reduction in tumor size ( approximately 90%) in comparison with mice treated with the vehicle alone. Tumor inhibition was related to severe induction of apoptosis. Moreover, neoangiogenesis was strongly inhibited (reduction of cells positive to vascular endothelial growth factor and CD31). Biochemical analyses of the cells, isolated by the primary lung tumor in alpha-CbT-treated mice, showed apoptosis features characterized by: (i) inhibition of BAD phosphorylation at Ser(112) and Ser(136); (ii) BAD dissociation from 14-3-3; (iii) BAD association with BCL-XL; and (iv) cleavage of caspase-9. Moreover, these cells were unable to grow in soft agar and develop tumor, when reinjected into mice. The small interfering RNA-mediated silencing of the alpha7-nAChR gene confirmed that alpha-CbT specifically inhibited the alpha7-nAChR-mediated survival pathway in A549 cells. Furthermore, the specificity of alpha-CbT is reinforced by the lack of effect of short chain toxin (Erabutoxin-a). Once more, the no effect of the low-affinity R33E-modified alpha-CbT strengthened the specificity of this inhibition. Although alpha7-nAChR antagonists, such as alpha-CbT, are unlikely to be a primary therapy, it may provide lead compounds for the design of clinically useful drugs.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1097-0215
pubmed:author
pubmed:issnType
Electronic
pubmed:day
1
pubmed:volume
125
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
199-211
pubmed:dateRevised
2010-6-4
pubmed:meshHeading
pubmed-meshheading:19326440-Animals, pubmed-meshheading:19326440-Apoptosis, pubmed-meshheading:19326440-Bungarotoxins, pubmed-meshheading:19326440-Carcinoma, Non-Small-Cell Lung, pubmed-meshheading:19326440-Cell Proliferation, pubmed-meshheading:19326440-Cobra Neurotoxin Proteins, pubmed-meshheading:19326440-Humans, pubmed-meshheading:19326440-Immunoprecipitation, pubmed-meshheading:19326440-Lung Neoplasms, pubmed-meshheading:19326440-Mice, pubmed-meshheading:19326440-Mice, Inbred NOD, pubmed-meshheading:19326440-Mice, Nude, pubmed-meshheading:19326440-Mice, SCID, pubmed-meshheading:19326440-Nicotinic Antagonists, pubmed-meshheading:19326440-RNA, Small Interfering, pubmed-meshheading:19326440-RNA Interference, pubmed-meshheading:19326440-Receptors, Nicotinic, pubmed-meshheading:19326440-Transplantation, Heterologous, pubmed-meshheading:19326440-Tumor Cells, Cultured
pubmed:year
2009
pubmed:articleTitle
Inhibition of non-neuronal alpha7-nicotinic receptor reduces tumorigenicity in A549 NSCLC xenografts.
pubmed:affiliation
Lung Cancer Unit, National Cancer Research Institute, Genoa, Italy.
pubmed:publicationType
Journal Article